Big Pharma Continues Pushing Myth That Solutions to Lower Rx Prices Will Hamper Innovation, While Trumpeting Robust and Growing Innovation Pipelines to Investors Big Pharma is having trouble keeping its story straight. While the pharmaceutical industry continues to falsely argue that legislation designed to lower prescription drug prices by holding them accountable will undermine innovation, […]
New Analysis Showcases How Big Pharma Raises Prices on Blockbuster Products With No Increase in Clinical Value for Patients A new analysis from the Institute of Clinical and Economical Review (ICER) finds that brand name drug makers’ unjustified price hikes on just eight prescription medications cost the U.S. an additional $1.2 billion in 2022. ICER’s most recent Unsupported […]
Greater List Price Transparency Will Help Deter Big Pharma’s Egregious Pricing Practices and Arm Patients and Providers With Critical Information A recent Forbes column criticizing the Drug-Price Transparency for Consumers Act (DTC Act) misses the key value of this bipartisan solution and the relationship between Big Pharma’s price-gouging and the industry’s blockbuster spending on direct-to-consumer […]
KFF Survey Finds Americans Want White House Contenders Talking Rx Prices, After Separate Poll Finds Voters Overwhelmingly Back Solutions to Hold Big Pharma Accountable In case you missed it, the Kaiser Family Foundation (KFF) released a new tracking poll revealing that Americans are concerned with the affordability of health care, and want to hear candidates […]
Analysis Finds Bogus and Faulty Patents Contribute to Rising Prescription Drug Launch Prices According to coverage in STAT News, a recent analysis published in the Journal of the American Medical Association (JAMA) found U.S. Food and Drug Administration (FDA) approved patents secured by Big Pharma are more frequently invalidated than any other industry sector due to […]
Another Blockbuster Quarter for Profits as Big Pharma Maintains Business-as-Usual Approach to Price Gouging Americans Eli Lilly, GlaxoSmithKline and AstraZeneca rounded out earnings calls for Big Pharma for the third quarter. All three Big Pharma firms reported earnings that topped Wall Street expectations after participating in price hikes earlier this year. Eli Lilly Eli Lilly […]
PhRMA Undercuts Own Rhetoric by Showing the Cancer Drug Pipeline is Growing Larger Oops. Big Pharma accidentally helped debunk one of the myths perpetuated by the pharmaceutical industry this week about the impact of drug pricing solutions on the innovation pipeline. In June, PhRMA distributed a press release on an industry-commissioned analysis claiming that drug […]
Commission Targets More Than 100 Patents on Brand Name Products Listed in the U.S. Food and Drug Administration’s Orange Book Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) issued a statement Tuesday reacting to an announcement from the Federal Trade Commission (FTC) that the Commission is challenging more than 100 patents listed in the U.S. […]
Another Series of Strong Earnings Reports For Brand Name Giants Fueled by Egregious Price Increases This week, Big Pharma giant AbbVie and Amgen both held earnings calls for the third quarter where they reported financials that topped Wall Street analysts’ expectations. The strong earnings follow price hikes earlier in the year from both brand name […]
Broad-based Coalition of Advocates, Including AARP and Patients for Affordable Drugs Now, Encourage Lawmakers to Boost Competition, Hold Big Pharma Accountable to Lower Drug Prices In case you missed it, on Wednesday, The Campaign for Sustainable Rx Pricing (CSRxP) joined more than 50 organizations, including AARP and Patients for Affordable Drugs Now, on a letter […]